Skip to content

Atea Pharmaceuticals, Inc.

AVIR· NasdaqCore metricsCIK 1593899

Pharmaceutical preparations552 peers

Last sale
Nov 2, 2026 · -0.12%
Market cap
$330.01M
80.3M shares
Filings
319
$351.37M
FY 2021+622.5% FY21 yoy
-$32.16M
Q3 2026N/M FY25 yoy
-$34.01M
Q3 2026N/M FY25 yoy
-$122.93M
FY 2022derivedN/M FY22 yoy
-$0.40
Q3 2026N/M FY25 yoy
$97.92M
Q3 2026+47.9% FY25 yoy
$330.01M
—
—
1.9×
—
—

FY2025 figures · derived

Price

$4.11+26.46%+$0.86past year
Nov 2, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$351.37MFY 2021
$351.37M0FY 2020FY 2021
PeriodEndedValueKindSource trail
FY 20212021-12-31$351,367,000reported
FY 20202020-12-31$48,633,000reported

Capital returns

Dividends and buybacks · FY2024 to FY2025
Fiscal yearDividendsBuybacksTotalPer shareSharesShares · yoyof free cash flow
FY2025—$25.52M$25.52M—79.67M sh−6.8%—
FY2024—$0.00$0.00—85.53M sh+1.6%—

Pharmaceutical preparations

Atea Pharmaceuticals, Inc. is the 213th largest of the 553 covered companies the SEC files under this code, by market cap. SIC 2834

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in market cap first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Atea Pharmaceuticals, Inc. · CIK 1593899 · Engraved from SEC EDGAR